Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Download Library

Download Library

Quickly sort and find the exact file you need here.

Title Date Documents

2017 ERS Conference: Reduction in Frequency of Pulmonary Exacerbations With Inhaled ARD-3150 in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients is Independent of Pseudomonas aeruginosa Susceptibility at Baseline

2017 World BE Conference Healthcare Cost and Utilization Before After Diagnosis Pseudomonas Aeruginosa Among Patients with Non Aeruginosa Among Patients with Non -cystic Fibrosis Bronchiectasis in the U.S.

2017 World BE Conference The Prevalence of Non -cystic Fibrosis Bronchiectasis in the U.S.

2017 World BE Conference Treatment Patterns Associated with Pseudomonas Aeruginosa Among Patients with Non Patients with Non -cystic Fibrosis Bronchiectasis in the U.S.

2017 ISAM Conference Inhaled Liposomal Ciprofloxacin for the
Prevention and Treatment of Severe Intracellular Lung Infections

2017 World BE Conference Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa Infection: Pharmacokinetics of Once-Daily Inhaled ARD-3150

2017 World BE Conference Inhaled Liposomal Ciprofloxacin in Patients With Bronchiectasis and Chronic Pseudomonas aeruginosa Infection: Results From Two Parallel Phase III Trials (ORBIT-3 and ORBIT-4)

2017 ISAM Conference Inhaled Liposomal Ciprofloxacin in Patients With Non-cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa Lung Infection

2015 Annual Report

Intensive Therapy With Inhaled Insulin via the AERx Insulin Diabetes Management System

CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.